{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Abbreviation', 'Explanation', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SC', 'subcutaneous', 'SD', 'standard deviation', 'SOC', 'system organ class', 'SUSAR', 'suspected unexpected serious adverse reaction', 'TdP', 'torsade des pointes', 'TEAE', 'treatment-emergent adverse event', 'TESAE', 'treatment-emergent serious adverse event', 'TpTe', 'Tpeak to Tend subinterval measurement', 'TSQM', 'Treatment Satisfaction Questionnaire for Medication', 'ULN', 'upper limit of normal', 'US', 'United States', 'WPAI', 'Work productivity and activity impairment questionnaire', '24']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '5.', 'INTRODUCTION', '5.1.', 'Background', 'Hereditary angioedema (HAE) with C1-esterase inhibitor (C1-INH) deficiency is an autosomal', 'dominant disorder characterized by recurrent episodes of swelling of the skin, pharynx, larynx,', 'gastrointestinal (GI) tract, genitals, and extremities (Longhurst and Cicardi 2012). The frequency', 'of attacks varies between subjects, from rarely in some patients to every few days in others.', 'Angioedema attacks may or may not be precipitated by a stimulus (such as stress, trauma, or', 'estrogen) and are typically rapid in onset, with symptoms subsiding gradually over the following', '3 to 5 days (Zuraw and Christiansen 2011). Oropharyngeal swelling can be life-threatening', '(Bork, Hardt et al. 2012), while attacks in other sites, including limbs, genitalia, face and', 'intestines, can be painful, disabling, and disfiguring, and have a significant impact on', 'functionality and quality of life (QoL) (Lumry, Castaldo et al. 2010). Although mortality risk', 'from asphyxiation is much higher in undiagnosed patients with HAE, deaths still occur in', 'diagnosed patients with access to care at centers of excellence (Bork, Hardt et al. 2012).', 'Extensive evidence from animal models and clinical studies supports the role of bradykinin (BK)', 'as the principal mediator of the signs and symptoms that characterize attacks of HAE (Han,', 'MacFarlane et al. 2002, Kaplan 2010, Zuraw and Christiansen 2011). Plasma kallikrein is a', 'serine protease integral to the contact activation pathway (Saxena, Thompson et al. 2011).', 'Kallikrein circulates in plasma as a zymogen, prekallikrein (PKK), bound to one of its main', 'substrates, high-molecular-weight kininogen (HK). During contact activation, PKK is cleaved by', 'activated factor XII, forming the active protease kallikrein. Kallikrein in turn cleaves HK,', 'producing BK (Kaplan and Ghebrehiwet 2010). The activation of the bradykinin B2 receptor by', 'BK ultimately results in vasodilatation, increased vascular permeability, and smooth muscle', 'contraction, all of which lead to the tissue swelling that characterizes HAE (Kaplan 2010).', 'BCX7353 is a potent, synthetic small molecule inhibitor of plasma kallikrein. In contrast to', 'parenterally administered options commercially available for prophylaxis against HAE attacks,', 'inhibition of kallikrein with an orally bioavailable small molecule such as BCX7353 offers the', 'advantage of oral administration.', '5.2.', 'Nonclinical Findings for BCX7353', 'The principal results of nonclinical pharmacology, pharmacokinetic (PK), and toxicology studies', 'of BCX7353 are described briefly below; additional details can be found in the BCX7353', \"Investigator's Brochure (IB).\", 'Safety pharmacology studies of BCX7353 indicated multiple cardiac ion channel effects,', 'including the human ether-a-go-go related gene K* channel and the Na and Ca2+ channels.', 'However, studies in non-human primates (NHP) showed quantitatively small drug-related', 'prolongation of the QT interval. There were no concerns for phototoxicity or genotoxicity.', 'Embryo-fetal developmental toxicity studies in the rat and rabbit showed no evidence of direct', 'fetal toxicity of BCX7353, and no effects were seen in male and female rats in fertility studies.', 'Chronic-dosing toxicology studies were conducted in the NHP (39 weeks) and rat (26 weeks).', 'BCX7353 was well tolerated in both rats and monkeys at doses up 30 and 20 mg/kg/day,', 'respectively, and these dose levels were the no observed adverse effect levels (NOAELs). In', '25']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'NHP, at the NOAEL dose of 30 mg/kg/day, mean maximal plasma concentration of the drug', '(Cmax) and area under the concentration VS. time curve (AUC) from time 0 to 24 hours (AUC0-24)', 'on Day 270 (sexes combined) were 277 ng/mL and 3950 ng.h/mL, respectively. In the rat, at the', 'NOAEL dose level of 20 mg/kg/day, Cmax was 686 ng/mL, and AUC0-24 was 9710 ng.h/mL, on', 'Day 182.', 'In the chronic toxicology study in rats the target organ was the liver. Minimal to mild bile duct', 'hyperplasia and foamy/pigmented macrophages were observed at 20 mg/kg/day. Vacuolated', 'epithelium of hepatic bile ducts was noted with minimal severity. A pathology peer-review of', 'liver findings in the 26-week study concluded that the microscopic changes, including bile duct', 'hyperplasia, were non-adverse.', 'In monkeys, the primary target organs were the liver and kidney. In one study that evaluated', 'doses up to 20 mg/kg/day, the only effect noted was a mild increase in alanine aminotransferase', '(ALT), which partially resolved during the study despite continued dosing. In a subsequent study', 'that evaluated doses of 30, 55, and 80 mg/kg/day, adverse findings in the liver and kidney were', 'noted at 55 and 80 mg/kg/day. Increased liver weights and panlobular hepatocellular hypertrophy', 'were observed together with increased ALT and aspartate aminotransferase (AST); and increased', 'kidney weights, renal tubular epithelial cell degeneration, and renal tubular hyperplasia were also', 'observed. Each of these effects were reversible during a 13-week drug-free recovery period.', 'In monkeys, pigmented and foamy macrophages were present in all regions of the small', 'intestine, in mesenteric lymph nodes and in liver Kupffer cells at doses > 30 mg/kg/day in', 'females, and at doses > 55 mg/kg/day in males. Dose-dependent increases in the urinary', 'concentrations of the experimental biomarker for phospholipidosis (PLD), di-docosahexaenoyl', '(22:6)- Bis(mono) acylglycerol phosphate (BMP), were observed in both rats and monkeys.', 'Electron microscopy evaluation of liver from rats in the 13-week toxicity studies demonstrated', 'myelinosomes within the cytoplasm of Kupffer cells. These effects are consistent with PLD, a', 'phenomenon noted in nonclinical toxicity studies with several approved drugs. PLD is', 'considered an adaptive response to the presence of a drug, rather than a toxic manifestation.', 'In monkeys, spleen and thymus weights were increased at 55 and 80 mg/kg/day. The increased', 'spleen weight correlated with lymphoid hyperplasia; there was no microscopic correlate for the', 'increased thymus weights.', '5.3.', 'Clinical Findings for BCX7353', 'A clinical program, including a comprehensive clinical pharmacology program of Phase 1', 'studies and 2 Phase 2 clinical studies (BCX7353-203 [CSR available; results summarized herein]', 'and BCX7353-204 [ongoing]) relevant to the current study have been conducted. One Phase 3', 'study (BCX7353-301) remains ongoing in Japan.', 'The principal results of clinical pharmacology, PK, and clinical safety and efficacy studies of', 'BCX7353 are described in the BCX7353 IB.', '26']\n\n###\n\n", "completion": "END"}